Highlights

  • Mayne Pharma shares rose 7.99% to AUD 2.90 on 29 April 2026 following its 3Q FY26 update.
  • DistributeRx launch delivered prescription volumes 72% above internal forecasts.
  • Group Revenue edged up 1% year-on-year to AUD 85.2 million.
  • Gross Margin expanded to 63%, up 400 basis points versus the prior period.
  • Underlying EBITDA improved 57% to AUD (1.4) million.
  • Adjusted Operating Cash Flow surged 90% to AUD 28.3 million.
  • Cash and marketable securities increased 29% to AUD 86.7 million

Mayne Pharma Group Ltd (ASX:MYX) shares moved higher by 7.99% to AUD 2.90 during the morning Trading session on 29 April 2026, following the release of its unaudited third-quarter FY26 (3Q FY26) results for the period ended 31 March 2026. While the stock remains significantly lower over the past year, today’s upward movement appears linked to operational progress, improved cash generation and early traction from its newly launched DistributeRx platform.

Mayne Pharma is a specialty pharmaceutical company focused on the development, manufacture and commercialisation of branded and generic pharmaceutical products, with core strengths in women’s health and dermatology. The company also provides contract development and Manufacturing services globally and has built a longstanding presence in oral drug delivery technologies. Its strategic direction centres on expanding commercial capabilities, improving access to medicines and leveraging its product portfolio across key markets, particularly in the United States and Australia.

DistributeRx Launch Drives Early Commercial Traction

A key development during the quarter was the launch of DistributeRx in March 2026, representing a shift in the company’s commercial strategy. The platform is designed to streamline prescription distribution while improving access for patients, prescribers and manufacturers.

Initial performance metrics indicate that prescription volumes significantly exceeded expectations. DistributeRx recorded volumes 72% ahead of internal forecasts, alongside a 73% increase compared to pre-launch February levels and a 92% rise relative to the prior corresponding period. Approximately 6,400 prescriptions were processed in March alone, highlighting early adoption.

The platform also expanded its network, onboarding around 1,600 new prescribers. Existing prescribers increased their activity by over 80% compared to pre-launch monthly averages. Despite operating with approximately 70% of its targeted salesforce capacity, the platform demonstrated scalability potential through increased territories and repeat prescriptions.

The dermatology portfolio available through DistributeRx includes 31 Mayne Pharma products and 178 third-party dermatology products, reflecting a broader ecosystem approach rather than a single-product strategy.

Financial Performance Reflects Gradual Improvement

For 3Q FY26, Mayne Pharma reported total Revenue of AUD 85.2 million, representing a modest increase of 1% compared to the prior corresponding period. Gross Profit rose by 8% to AUD 53.4 million, supported by pricing discipline, product mix optimisation and improved channel execution, resulting in a gross Margin of 63%, up from 59% a year earlier.

Direct contribution increased by 11% to AUD 17.9 million, indicating improved operational efficiency. Reported EBITDA remained negative at AUD 4.5 million but showed a 10% improvement year-on-year. More notably, underlying EBITDA improved to a loss of AUD 1.4 million, narrowing significantly from a loss of AUD 3.3 million in the prior period, reflecting a 57% improvement.

Net loss after tax also reduced to AUD 21.0 million from AUD 22.5 million, indicating incremental progress in overall profitability.

Cash Flow Strength and Balance Sheet Expansion

A notable feature of the quarter was the improvement in Cash Flow generation. Adjusted Operating Cash Flow from continuing operations rose sharply by 90% to AUD 28.3 million. The company attributed this increase primarily to the timing of certain gross-to-net (GTN) cash payments, which are expected to occur in the following quarter.

Net Cash Flow for the period stood at AUD 19.3 million, contributing to a 29% increase in cash and marketable securities, which reached AUD 86.7 million as of 31 March 2026. This enhanced Liquidity position provides flexibility for reinvestment into growth initiatives and potential Business development opportunities.

Cash flows from discontinued operations declined by 30% to AUD 1.4 million, reflecting the company’s ongoing transition toward its core operating segments.

Women’s Health Portfolio Shows Prescription Growth

The Women’s Health segment continued to contribute to overall performance, supported by increased prescription volumes across key products. Total prescriptions for BIJUVA rose by 30% compared to the prior period, while NEXTSTELLIS Demand cycles increased by 12%.

Segment Revenue reached US$26.4 million, reflecting a 7% increase year-on-year. NEXTSTELLIS generated net sales of US$11.7 million, up 19%, while BIJUVA recorded net sales growth of 26% to US$3.7 million. IMVEXXY prescriptions increased by 4%, although net sales declined by 12%, and ANNOVERA prescriptions decreased slightly by 2%, with flat Revenue performance.

An important regulatory development during the quarter was the update to BIJUVA labelling by the U.S. Food and Drug Administration (FDA), which removed certain warnings related to cardiovascular risk, breast cancer and probable dementia. This change is expected to influence prescribing behaviour by improving confidence among healthcare providers.

The company also noted a temporary Supply disruption for BIJUVA due to increased Demand, with Supply expected to normalise in the near term.

Dermatology Segment Supported by Portfolio Performance

Within dermatology, Mayne Pharma reported continued prescription growth in its generic ACCUTANE product, with Market Share increasing from 51% to 61% compared to the prior period. This gain was supported by a targeted digital health Partnership.

RHOFADE maintained stable prescription volumes and Market Share, while TWYNEO benefited from improved formulary coverage, facilitating patient access. AG ORACEA held a 47% Market Share despite ongoing generic competition.

The dermatology segment generated Revenue of US$20.5 million, up 1% year-on-year. Gross Profit increased by 34% to US$12.8 million, with gross Margin expanding significantly to 63%. Direct contribution rose by 55% to US$4.7 million, reflecting improved cost management and operational execution.

International Business Builds Momentum

The International segment recorded Revenue growth of 19% to AUD 17.7 million, driven by increased Demand for NEXTSTELLIS in Australia following its inclusion in the Pharmaceutical Benefits Scheme (PBS) and expanded distribution of KADIAN in Canada.

NEXTSTELLIS prescriptions in Australia increased by approximately 160% in 3Q FY26 compared to the quarter prior to PBS listing, indicating improved accessibility and awareness.

Gross Profit for the segment rose by 4% to AUD 4.6 million, although gross Margin declined to 26%. Direct contribution decreased by 6% to AUD 1.0 million.

The company also highlighted ongoing efforts to expand international partnerships, including out-licensing discussions in Asian markets and participation in industry conferences across Japan, China and Korea.

Operational Context and Outlook

The third quarter typically presents seasonal challenges due to the reset of U.S. patient insurance deductibles, which increases out-of-pocket costs and impacts Demand, while also elevating GTN expenses. Despite this, Mayne Pharma reported stable Revenue and improved margins, indicating resilience in its operating model.

Looking ahead, the company intends to continue investing in its Women’s Health and Dermatology segments, while expanding the DistributeRx ecosystem. It is also evaluating Capital allocation Options, including the potential for an on-Market Share buy-back.

What This Means for Investors?

The share price increase on 29 April 2026 appears to reflect investor response to improving operational indicators, including stronger Cash Flow, Margin expansion and early success of the DistributeRx initiative. While Revenue growth remained modest and Earnings are still negative, the narrowing losses and enhanced Liquidity position suggest gradual progress.

The performance of key products in Women’s Health, combined with dermatology Market Share gains and international expansion, indicates multiple areas of operational activity. Investors may continue to monitor execution in the coming quarters, particularly the scalability of DistributeRx and the conversion of prescription growth into sustained financial performance.